Supervisor Database Search
Guidance for ICAT Supervisors
The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year.
You can read about the ICAT supervisor selection process and eligibility criteria below:
Terms of reference/guide to supervising ICAT Fellows.
You can read the terms of reference for supervisors actively supervising ICAT Fellows below:
Supervisor Database
Search for supervisors below. You can filter your search using the options and select multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.
Full NameDr Kate Connor
- cancer/oncology
- neuroscience and mental health
- Medicine
- Surgery
- Veterinary Medicine
- Neurology
- Neurophysiology
- Oncology
- Physiology
Our group integrates tumour biology, cancer neuroscience, and translational imaging to address key challenges in difficult-to-treat malignancies, with a particular focus on glioblastoma (GBM) and brain tumour–related epilepsy (BTRE). We develop and refine advanced, clinically relevant preclinical models to interrogate mechanisms of therapeutic resistance and identify tumour microenvironment (TME) contexts of vulnerability. This work has contributed to defining novel GBM TME subtypes with implications for precision immunotherapy (Annals of Oncology, 2022). A major research strand centres on cancer neuroscience, where we investigate mechanisms of epileptogenesis in BTRE using state-of-the-art in vivo, ex vivo, and electrophysiological approaches. Ongoing projects explore gene therapy strategies, the neuroinflammatory contribution of the innate immune system (in particular mast cells), and neurotransmitter-based therapeutic targets. Lastly, our group aims to develop CT- and MR-radiomics pipelines for monitoring disease progression and treatment response in intracranial tumours, building on recent demonstrations of clinically relevant CT-radiomics workflows (Scientific Reports, 2024).
Together, these interdisciplinary programmes aim to advance precision therapies, improve patient stratification, and refine translational pathways for neuro-oncology research.
Prof Mark Cunningham
Prof Annette Byrne